Kristen Johnson, Ph.D.

Kristen Johnson, Ph.D.

Senior Director, IBD

Kristy Johnson has over 15 years of experience in industry and academia, with deep expertise in both immunology and rare disease. Kristy has a strong track record of delivering impact across diverse initiatives including: project leadership, development and implementation of R&D strategies, building high-performing teams and fostering collaborations across industry, academia and patient foundations. At Celsius, she leads target identification/validation, early drug discovery, and clinical partnerships across the company’s IBD portfolio.

Kristy joined Celsius in 2021 from Boehringer Ingelheim, where she led IBD disease positioning efforts by: supporting the differentiation of portfolio assets, identifying novel biology in patients not adequately treated by standard of care and leading external collaborations. Previously Kristy spent over 7 years at Pfizer’s Center of Therapeutic Innovation, an external facing R&D research unit that partnered with leading medical centers in early drug discovery programs. During her time at Pfizer she led programs in both rare disease and autoimmunity from early discovery to Proof of Concept in the clinic.

Kristy obtained her Ph.D. from Columbia University and completed her postdoctoral training at the University of Chicago and NYU under the support of Leukemia & Lymphoma Society Fellowship and a NIH K99 Award.